Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Upadacitinib (ABT-494) to placebo and to adalimumab in adults with rheumatoid arthritis inadequately responsive to methotrexate; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-10-07